We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Brian Rini

Brian I. Rini MD, FACP

Professor of Medicine, Lerner College of Medicine, Department of Solid Tumor Oncology, Cleveland Clinic Taussig Cancer Institute, Glickman Urological Institute, Cleveland, Ohio

Brian I. Rini, MD, FACP is a Professor of Medicine at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University in Cleveland, Ohio. A Staff member of the Department of Solid Tumor Oncology and Co-Leader of the Genitourinary Program of the CASE Comprehensive Cancer Center, Dr. Rini’s work focuses on genitourinary malignancies.

Dr. Rini earned his medical degree at the Ohio State University College of Medicine. Dr. Rini completed a Residency program in Internal Medicine and a Fellowship in Hematology / Oncology at University of Chicago Hospitals. Dr. Rini was an Assistant Professor at the University of California San Francisco before moving to The Cleveland Clinic.

Dr. Rini’s primary research has been in renal cell carcinoma (RCC) and prostate cancer, with special focus on antiangiogenic therapy and immunotherapy. Dr. Rini has been involved in the initial and ongoing development of targeted agents for metastatic RCC, and was an integral investigator in the clinical development of several agents which are now FDA approved. Dr. Rini was the Principal Investigator of an international phase III cooperative group trial of bevacizumab plus interferon and the PI of the phase III axitinib trial in metastatic RCC that lead to FDA approval, and is currently the PI of several global phase III trials in RCC.

Dr. Rini’s research has been published in peer-reviewed journals that include Journal of the National Cancer Institute, Journal of Clinical Oncology, Cancer, Lancet and JAMA.  He is a member of the editorial boards of Journal of Clinical Oncology and Co-Chair of the NCI RCC Task Force.